Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: A review of cases reported to the U.S. Food and drug administration adverse event reporting system

Annals of Internal Medicine

Volumn 166, Issue 11, 2017, Pages 792-798

  Bersoff Matcha, Susan J ^a   Cao, Kelly ^a   Jason, Mihaela ^a   Ajao, Adebola ^a   Jones, S Christopher ^a   Meyer, Tamra ^a   Brinker, Allen ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASUNAPREVIR; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; EMTRICITABINE; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CASE STUDY; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CLINICAL LABORATORY; CLINICAL OUTCOME; COMBINATION DRUG THERAPY; DEATH; DESCRIPTIVE RESEARCH; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FATIGUE; FEMALE; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATOMEGALY; HUMAN; JAUNDICE; LIVER TRANSPLANTATION; LOSS OF APPETITE; MALAISE; MALE; MIXED INFECTION; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; UNITED STATES; VIRUS DETECTION; VIRUS INTERFERENCE; VIRUS LOAD; VIRUS REACTIVATION; WEAKNESS; CHEMICAL AND DRUG INDUCED LIVER INJURY; COMPLICATION; HEPATITIS C, CHRONIC; MIDDLE AGED; PHYSIOLOGY; VERY ELDERLY; VIROLOGY; VIRUS ACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; COINFECTION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VIRUS ACTIVATION;

EID: 85020750860     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M17-0377     Document Type: Article

References (44)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 1999;6:35-47. [PMID: 10847128
2. Centers for Disease Control and Prevention. Viral hepatitis-hepatitis C information. Overview and statistics. 2017. Accessed at www.cdc.gov/hepatitis/hcv/hcvfaq.htm#section1 on 18 March 2017.
3. Centers for Disease Control and Prevention. Viral hepatitis-hepatitis C information. Hepatitis C FAQs for health professionals. Accessed at www.cdc.gov/hepatitis/hcv/hcvfaq.htm on 15 March 2017.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65. [PMID: 11583749
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82. [PMID: 12324553
6. Gutierrez JA, Lawitz EJ, Poordad F. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. J Viral Hepat. 2015;22:861-70. [PMID: 26083155] doi:10.1111/jvh.12422
7. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211-21. [PMID: 24428467] doi:10.1056/NEJMoa1306218
8. Everson GT, Sims KD, Rodriguez-Torres M, Hezode C, Lawitz E, Bourlière M, et al. Efficacy of an interferon-and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology. 2014; 146:420-9. [PMID: 24184132] doi:10.1053/j.gastro.2013.10.057
9. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584-93. [PMID: 23268517] doi:10.1001/jama.2012.144878
10. Innes HA, McDonald SA, Dillon JF, Allen S, Hayes PC, Goldberg D, et al. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology. 2015;62:355-64. [PMID: 25716707] doi:10.1002/hep.27766
11. Centers for Disease Control and Prevention. Viral hepatitis-hepatitis B information. 2015. Accessed at www.cdc.gov/hepatitis/hbv on 15 March 2017.
12. Sagnelli E, Coppola N, Marrocco C, Onofrio M, Sagnelli C, Coviello G, et al. Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course. J Clin Virol. 2006;35:317-20. [PMID: 16316779
13. Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viral interactions and management. Ann Gastroenterol. 2015;28:221-8. [PMID: 25830779
14. Bini EJ, Perumalswami PV. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions. Hepatology. 2010;51:759-66. [PMID: 20140950] doi:10.1002/hep.23461
15. Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2013;58:538-45. [PMID: 23505059] doi:10.1002/hep.26400
16. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-62. [PMID: 10451460
17. Siddiqui F, Mutchnick M, Kinzie J, Peleman R, Naylor P, Ehrinpreis M. Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. Am J Gastroenterol. 2001;96:858-63. [PMID: 11280565
18. Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49: S156-65. [PMID: 19399803] doi:10.1002/hep.22945
19. Manegold C, Hannoun C, Wywiol A, Dietrich M, Polywka S, Chiwakata CB, et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2001;32:144-8. [PMID: 11118394
20. Kato M, Atsumi T, Kurita T, Odani T, Fujieda Y, Otomo K, et al. Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in hepatitis B surface antigen-negative cases. J Rheumatol. 2011;38:2209-14. [PMID: 21844146] doi:10.3899/jrheum.110289
21. John S, Andersson KL, Kotton CN, Hertl M, Markmann JF, Cosimi AB, et al. Prophylaxis of hepatitis B infection in solid organ transplant recipients. Therap Adv Gastroenterol. 2013;6:309-19. [PMID: 23814610] doi:10.1177/1756283X13487942
22. Reddy NM, Savani BN. Hepatitis B reactivation in patients with hematological malignancies and stem cell transplantation. J Blood Lymph. 2013;4:114. doi:10.4172/2165-7831.1000114
23. Liu JY, Sheng YJ, Hu HD, Zhong Q, Wang J, Tong SW, et al. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis. Virol J. 2012;9:186. [PMID: 22950520] doi:10.1186/1743-422X-9-186
24. Kessler DA. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA. 1993;269:2765-8. [PMID: 8492403
25. Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20 Suppl C:C40-4. [PMID: 9915089
26. Ende AR, Kim NH, Yeh MM, Harper J, Landis CS. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep. 2015;9:164. [PMID: 26215390] doi:10.1186/s13256-015-0630-8
27. Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2017;15:132-6. [PMID: 27392759] doi:10.1016/j.cgh .2016.06.023
28. Balagopal A, Thio CL. Editorial commentary: another call to cure hepatitis B [Editorial]. Clin Infect Dis. 2015;61:1307-9. [PMID: 26082512] doi:10.1093/cid/civ475
29. Collins JM, Raphael KL, Terry C, Cartwright EJ, Pillai A, Anania FA, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis. 2015; 61:1304-6. [PMID: 26082511] doi:10.1093/cid/civ474
30. Suga T, Sato K, Yamazaki Y, Ohyama T, Horiguchi N, Kakizaki S, et al. Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir. World J Clin Cases. 2015;3:1005-10. [PMID: 26677451] doi:10.12998/wjcc.v3.i12.1005
31. Shibata S, Umemura T, Komatsu M, Tanaka E. Severe hepatotoxicity associated with asunaprevir and daclatasvir in chronic hepatitis C [Letter]. Hepatology. 2016;63:2063-4. [PMID: 26248724] doi:10.1002/hep.28113
32. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-83. [PMID: 26566064] doi:10.1002/hep.28156
33. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22:1170-80. [PMID: 21115603] doi: 10.1093/annonc/mdq583
34. Montiel PM, Solis JA, Chirinos JA, a Casis B, Sánchez F, Rodrí-guez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient [Letter]. Liver Int. 2008;28:718-20. [PMID: 18433400] doi:10.1111/j.1478-3231.2007 .01665.x
35. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209-20. [PMID: 16440366
36. Walker EJ, Simko JP, Ko AH. Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor. Anticancer Res. 2014;34:3629-34. [PMID: 24982379
37. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT; American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215-9. [PMID: 25447850] doi:10.1053/j.gastro.2014.10.039
38. De Monte A, Courjon J, Anty R, Cua E, Naqvi A, Mondain V, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016;78:27-30. [PMID: 26967675] doi:10.1016/j .jcv.2016.02.026
39. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing and treating hepatitis C. 2017. Accessed at www.hcvguidelines.org on 15 March 2017.
40. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015;163:215-23. [PMID: 26120969] doi:10.7326/M15-0406
41. Kottilil S, Wright M, Polis MA, Masur H. Treatment of hepatitis C virus infection: is it time for the internist to take the reins? Ann Intern Med. 2014;161:443-4. [PMID: 25222390] doi:10.7326/M14-0741
42. Takayama H, Sato T, Ikeda F, Fujiki S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res. 2016;46:489-91. [PMID: 26297529] doi:10.1111/hepr.12578
43. Kimura H, Ohkawa K, Sakakibara M, Imanaka K, Matsunaga T, Miyazaki M, et al. Sustained hepatitis C virus RNA clearance accompanied by elevation of hepatitis B virus DNA after short-term peginterferon-α, ribavirin and simeprevir therapy in chronic hepatitis patient having dual infection with hepatitis B and C viruses. Kanzo 2015;56:422-7.
44. Ou P, Fang Z, Chen J. Hepatitis B reactivation in a chronic hepatitis C patient treated with ledipasvir and sofosbuvir: a case report. Clin Res Hepatol Gastroenterol. 2017;41:e17-18. [PMID: 27601170] doi:10.1016/j.clinre.2016.08.001